title: [New inhibitors of adrenal androgen synthesis enzymes].
abstract: The androgen sensitivity of prostate cancer is enhanced during hormonal therapy and prostate cancer develops to CRPC in response to DHT of low concentration synthesized from adrenal androgen and signals (cytokines) that activate androgen receptor (AR). New medicines in consideration of these mechanisms were developed recently. They are already used for a clinic abroad, or clinical studies are conducted, and may be introduced in near future in Japan. Therefore, it is extremely important that we master fundamental knowledge of the new medicines for CRPC. Here, I want to describe adrenal androgen synthesis inhibitors among medicines targeting Androgen-AR axis.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Mizokami
mesh_terms: D000726:Androgen Antagonists / Q000737:chemistry / Q000627:therapeutic use*; D000728:Androgens / Q000096:biosynthesis*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D011944:Receptors, Androgen / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D013254:Steroid 17-alpha-Hydroxylase / Q000037:antagonists & inhibitors*
chemical_list: D000726:Androgen Antagonists; D000728:Androgens; D011944:Receptors, Androgen; C501892:CYP17A1 protein, human; D013254:Steroid 17-alpha-Hydroxylase